HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management (original) (raw)

• Chaturvedi, A. K. et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J. Clin. Oncol. 29, 4294–4301 (2011).
  PubMed PubMed Central Google Scholar
• Gillison, M. L., Chaturvedi, A. K., Anderson, W. F. & Fakhry, C. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J. Clin. Oncol. 33, 3235–3242 (2015).
  CAS PubMed PubMed Central Google Scholar
• Senkomago, V. et al. Human papillomavirus-attributable cancers — United States, 2012–2016. MMWR Morb. Mortal. Wkly Rep. 68, 724–728 (2019).
  PubMed PubMed Central Google Scholar
• Schache, A. G. et al. HPV-related oropharynx cancer in the United Kingdom: an evolution in the understanding of disease etiology. Cancer Res. 76, 6598–6606 (2016).
  CAS PubMed Google Scholar
• Lei, J. et al. HPV vaccination and the risk of invasive cervical cancer. N. Engl. J. Med. 383, 1340–1348 (2020).
  CAS PubMed Google Scholar
• Craig, S. G. et al. Recommendations for determining HPV status in patients with oropharyngeal cancers under TNM8 guidelines: a two-tier approach. Br. J. Cancer 120, 827–833 (2019).
  PubMed PubMed Central Google Scholar
• Gillison, M. L. et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J. Natl Cancer Inst. 100, 407–420 (2008).
  PubMed Google Scholar
• Lechner, M., Jones, O. S., Breeze, C. E. & Gilson, R. Gender-neutral HPV vaccination in the UK, rising male oropharyngeal cancer rates, and lack of HPV awareness. Lancet Infect. Dis. 19, 131–132 (2019).
  PubMed Google Scholar
• Faraji, F. et al. The prevalence of human papillomavirus in oropharyngeal cancer is increasing regardless of sex or race, and the influence of sex and race on survival is modified by human papillomavirus tumor status. Cancer 125, 761–769 (2019).
  PubMed Google Scholar
• Argirion, I. et al. Increasing prevalence of HPV in oropharyngeal carcinoma suggests adaptation of p16 screening in Southeast Asia. J. Clin. Virol. 132, 104637 (2020).
  CAS PubMed Google Scholar
• Hwang, T. Z., Hsiao, J. R., Tsai, C. R. & Chang, J. S. Incidence trends of human papillomavirus-related head and neck cancer in Taiwan, 1995-2009. Int. J. Cancer 137, 395–408 (2015).
  CAS PubMed Google Scholar
• Wittekindt, C. et al. Increasing incidence rates of oropharyngeal squamous cell carcinoma in Germany and significance of disease burden attributed to human papillomavirus. Cancer Prev. Res. 12, 375–382 (2019).
  CAS Google Scholar
• Zamani, M. et al. The current epidemic of HPV-associated oropharyngeal cancer: an 18-year Danish population-based study with 2,169 patients. Eur. J. Cancer 134, 52–59 (2020).
  CAS PubMed Google Scholar
• Del Mistro, A. et al. Age-independent increasing prevalence of human papillomavirus-driven oropharyngeal carcinomas in North-East Italy. Sci. Rep. 10, 1–10 (2020).
  Google Scholar
• Morbini, P. et al. The evolving landscape of human papillomavirus-related oropharyngeal squamous cell carcinoma at a single institution in northern Italy. Acta Otorhinolaryngol. Ital. 39, 9–17 (2019).
  CAS PubMed PubMed Central Google Scholar
• Haeggblom, L. et al. Changes in incidence and prevalence of human papillomavirus in tonsillar and base of tongue cancer during 2000-2016 in the Stockholm region and Sweden. Head. Neck 41, 1583–1590 (2019).
  PubMed Google Scholar
• Donà, M. G. et al. Evolving profile of HPV-driven oropharyngeal squamous cell carcinoma in a national cancer institute in Italy: a 10-year retrospective study. Microorganisms 8, 1–12 (2020).
  Google Scholar
• Girardi, F. M., Wagner, V. P., Martins, M. D., Abentroth, A. L. & Hauth, L. A. Prevalence of p16 expression in oropharyngeal squamous cell carcinoma in southern Brazil. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. 130, 681–691 (2020).
  PubMed Google Scholar
• Rietbergen, M. M. et al. Epidemiologic associations of HPV-positive oropharyngeal cancer and (pre)cancerous cervical lesions. Int. J. Cancer 143, 283–288 (2018).
  CAS PubMed Google Scholar
• Carlander, A. F. et al. A contemporary systematic review on repartition of HPV-positivity in oropharyngeal cancer worldwide. Viruses 13, 1326 (2021).
  CAS PubMed PubMed Central Google Scholar
• Chen, S. Y. et al. The association of smoking and outcomes in HPV-positive oropharyngeal cancer: a systematic review. Am. J. Otolaryngol. 41, 102592 (2020).
  PubMed Google Scholar
• Ang, K. K. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363, 24–35 (2010).
  CAS PubMed PubMed Central Google Scholar
• Gooi, Z., Chan, J. Y. K. & Fakhry, C. The epidemiology of the human papillomavirus related to oropharyngeal head and neck cancer. Laryngoscope 126, 894–900 (2016).
  PubMed Google Scholar
• D’Souza, G. et al. Sex differences in risk factors and natural history of oral human papillomavirus infection. J. Infect. Dis. 213, 1893–1896 (2016).
  PubMed Google Scholar
• de Martel, C., Plummer, M., Vignat, J. & Franceschi, S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int. J. Cancer 141, 664–670 (2017).
  PubMed PubMed Central Google Scholar
• Blumberg, J., Monjane, L., Prasad, M., Carrilho, C. & Judson, B. L. Investigation of the presence of HPV related oropharyngeal and oral tongue squamous cell carcinoma in Mozambique. Cancer Epidemiol. 39, 1000–1005 (2015).
  PubMed PubMed Central Google Scholar
• Rettig, E. M. et al. Oral human papillomavirus infection and head and neck squamous cell carcinoma in rural northwest Cameroon. OTO Open 3, 2473974X18818415 (2019).
  PubMed PubMed Central Google Scholar
• Ndiaye, C. et al. The role of human papillomavirus in head and neck cancer in Senegal. Infect. Agent. Cancer 8, 14 (2013).
  CAS PubMed PubMed Central Google Scholar
• Kofi, B. et al. Infrequent detection of human papillomavirus infection in head and neck cancers in the Central African Republic: a retrospective study. Infect. Agent Cancer 14, 9 (2019).
  PubMed PubMed Central Google Scholar
• Oga, E. A. et al. Paucity of HPV-related head and neck cancers (HNC) in Nigeria. PLoS ONE 11, e0152828 (2016).
  PubMed PubMed Central Google Scholar
• Chaturvedi, A. K. & Zumsteg, Z. S. A snapshot of the evolving epidemiology of oropharynx. cancers Cancer 124, 2893–2896 (2018).
  PubMed Google Scholar
• Tota, J. E. et al. Evolution of the oropharynx cancer epidemic in the United States: moderation of increasing incidence in younger individuals and shift in the burden to older individuals. J. Clin. Oncol. 37, 1538–1546 (2019).
  CAS PubMed PubMed Central Google Scholar
• Kreimer, A. R. et al. Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. Oral. Oncol. 108, 104736 (2020).
  CAS PubMed PubMed Central Google Scholar
• Mariz BALA, K. L. P. et al. Global prevalence of human papillomavirus-driven oropharyngeal squamous cell carcinoma following the ASCO guidelines: a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 156, 103116 (2020).
  PubMed Google Scholar
• Windon, M. J. et al. Increasing prevalence of human papillomavirus–positive oropharyngeal cancers among older adults. Cancer 124, 2993–2999 (2018).
  CAS PubMed Google Scholar
• Rettig, E. M., Fakhry, C., Khararjian, A. & Westra, W. H. Age profile of patients with oropharyngeal squamous cell carcinoma. JAMA Otolaryngol. 144, 538–539 (2018).
  Google Scholar
• Zumsteg, Z. S. et al. Incidence of oropharyngeal cancer among elderly patients in the United States. JAMA Oncol. 2, 1617–1623 (2016).
  PubMed Google Scholar
• Mahal, B. A. et al. Incidence and demographic burden of HPV-associated oropharyngeal head and neck cancers in the United States. Cancer Epidemiol. Biomark. Prev. 28, 1660–1667 (2019).
  Google Scholar
• Ramer, I. et al. Racial disparities in incidence of human papillomavirus-associated oropharyngeal cancer in an urban population. Cancer Epidemiol. 44, 91–95 (2016).
  PubMed Google Scholar
• Liederbach, E. et al. The national landscape of human papillomavirus-associated oropharynx squamous cell carcinoma. Int. J. Cancer 140, 504–512 (2017).
  CAS PubMed Google Scholar
• Falcaro, M. et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet 398, 2084–2092 (2021).
  PubMed Google Scholar
• Masterson, L. & Lechner, M. HPV vaccination in boys — will the UK join the fight? Nat. Rev. Clin. Oncol. 13, 721–722 (2016).
  PubMed Google Scholar
• HPV Vaccination Uptake. Australia National Control Indicators. Published 2019. https://ncci.canceraustralia.gov.au/prevention/hpv-vaccination-uptake/hpv-vaccination-uptake (2021).
• Walker, T. Y. et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years — United States, 2019. MMWR Morb. Mortal. Wkly Rep. 69, 1109–1116 (2020).
  Google Scholar
• Public Health England. Human papillomavirus (HPV) vaccination coverage in adolescent females and males in England: academic year 2019 to 2020. Heal. Prot. Rep. 14, 1–15 (2020).
  Google Scholar
• Radisic, G., Chapman, J., Flight, I. & Wilson, C. Factors associated with parents’ attitudes to the HPV vaccination of their adolescent sons: a systematic review. Prev. Med. 95, 26–37 (2017).
  PubMed Google Scholar
• Sonawane, K. et al. Parental intent to initiate and complete the human papillomavirus vaccine series in the USA: a nationwide, cross-sectional survey. Lancet Public Heal. 5, e484–e492 (2020).
  Google Scholar
• Gottvall, M., Stenhammar, C. & Grandahl, M. Parents’ views of including young boys in the Swedish national school-based HPV vaccination programme: a qualitative study. BMJ Open 7, 11–13 (2017).
  Google Scholar
• Thompson, E. L. et al. Awareness and knowledge of HPV and HPV vaccination among adults ages 27–45 years. Vaccine 38, 3143–3148 (2020).
  PubMed Google Scholar
• Waller, J. et al. Decision-making about HPV vaccination in parents of boys and girls: a population-based survey in England and Wales. Vaccine 38, 1040–1047 (2020).
  CAS PubMed PubMed Central Google Scholar
• Sherman, S. M., Cohen, C. R., Denison, H. J., Bromhead, C. & Patel, H. A survey of knowledge, attitudes and awareness of the human papillomavirus among healthcare professionals across the UK. Eur. J. Public Health 30, 10–16 (2020).
  PubMed Google Scholar
• Lechner, M. et al. A cross-sectional survey of awareness of human papillomavirus-associated oropharyngeal cancers among general practitioners in the UK. BMJ Open 8, 1–6 (2018).
  Google Scholar
• Katz, J. The impact of HPV vaccination on the prevalence of oropharyngeal cancer (OPC) in a hospital-based population: a cross-sectional study of patient’s registry. J. Oral. Pathol. Med. 50, 47–51 (2021).
  CAS PubMed Google Scholar
• Herrero, R. et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS ONE 8, e68329 (2013).
  CAS PubMed PubMed Central Google Scholar
• Chaturvedi, A. K. et al. Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. J. Clin. Oncol. 36, 262–267 (2018).
  CAS PubMed Google Scholar
• Hirth, J. M., Chang, M., Resto, V. A., Guo, F. & Berenson, A. B. Prevalence of oral human papillomavirus by vaccination status among young adults (18–30 years old). Vaccine 35, 3446–3451 (2017).
  PubMed Google Scholar
• Zhang, Y., Fakhry, C. & D’Souza, G. Projected association of human papillomavirus vaccination with oropharynx cancer incidence in the US, 2020–2045. JAMA Oncol. 7, e212907 (2021).
  PubMed Google Scholar
• Lechner, M., Breeze, C. E., O’Mahony, J. F. & Masterson, L. Early detection of HPV-associated oropharyngeal cancer. Lancet 393, 2123 (2019).
  PubMed Google Scholar
• Kreimer, A. R. et al. Timing of HPV16-E6 antibody seroconversion before OPSCC: findings from the HPVC3 consortium. Ann. Oncol. 30, 1335–1343 (2019).
  CAS PubMed PubMed Central Google Scholar
• Kreimer, A. R., Clifford, G. M., Boyle, P. & Franceschi, S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systemic review. Cancer Epidemiol. Biomark. Prev. 14, 467–475 (2005).
  CAS Google Scholar
• Egawa, N., Egawa, K., Griffin, H. & Doorbar, J. Human papillomaviruses; epithelial tropisms, and the development of neoplasia. Viruses 7, 3863–3890 (2015).
  CAS PubMed PubMed Central Google Scholar
• Doorbar, J. et al. The biology and life-cycle of human papillomaviruses. Vaccine 30, F55–F70 (2012).
  CAS PubMed Google Scholar
• Graham, S. V. Keratinocyte differentiation-dependent human papillomavirus gene regulation. Viruses 9, 245 (2017).
  PubMed Central Google Scholar
• Parfenov, M. et al. Characterization of HPV and host genome interactions in primary head and neck cancers. Proc. Natl Acad. Sci. USA 111, 15544–15549 (2014).
  CAS PubMed PubMed Central Google Scholar
• Vinokurova, S. et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 68, 307–313 (2008).
  CAS PubMed Google Scholar
• Ramqvist, T. et al. Studies on human papillomavirus (HPV) 16 E2, E5 and E7 mRNA in HPV-positive tonsillar and base of tongue cancer in relation to clinical outcome and immunological parameters. Oral. Oncol. 51, 1126–1131 (2015).
  CAS PubMed Google Scholar
• Koneva, L. A. et al. HPV integration in HNSCC correlates with survival outcomes, immune response signatures, and candidate drivers. Mol. Cancer Res. 16, 90–102 (2018).
  CAS PubMed Google Scholar
• Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
  CAS PubMed Google Scholar
• Mesri, E. A., Feitelson, M. A. & Munger, K. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe 15, 266–282 (2014).
  CAS PubMed PubMed Central Google Scholar
• Huibregtse, J. M., Scheffner, M. & Howley, P. M. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 10, 4129–4135 (1991).
  CAS PubMed PubMed Central Google Scholar
• Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J. & Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129–1136 (1990).
  CAS PubMed Google Scholar
• Scheffner, M., Huibregtse, J. M., Vierstra, R. D. & Howley, P. M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75, 495–505 (1993).
  CAS PubMed Google Scholar
• Huh, K. et al. Human papillomavirus type 16 E7 oncoprotein associates with the Cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J. Virol. 81, 9737–9747 (2007).
  CAS PubMed PubMed Central Google Scholar
• Dyson, N., Howley, P. M., Munger, K. & Harlow, E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243, 934–938 (1986).
  Google Scholar
• Münger, K., Phelps, W. C., Bubb, V., Howley, P. M. & Schlegel, R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63, 4417–4421 (1989).
  PubMed PubMed Central Google Scholar
• Božinović, K. et al. Genome-wide miRNA profiling reinforces the importance of miR-9 in human papillomavirus associated oral and oropharyngeal head and neck cancer. Sci. Rep. 9, 2306 (2019).
  PubMed PubMed Central Google Scholar
• Boscolo-Rizzo, P., Furlan, C., Lupato, V., Polesel, J. & Fratta, E. Novel insights into epigenetic drivers of oropharyngeal squamous cell carcinoma: role of HPV and lifestyle factors. Clin. Epigenetics 9, 124 (2017).
  PubMed PubMed Central Google Scholar
• Barr, J. A. et al. Long non-coding RNA FAM83H-AS1 is regulated by human papillomavirus 16 E6 independently of p53 in cervical cancer cells. Sci. Rep. 9, 3662 (2019).
  PubMed PubMed Central Google Scholar
• Lechner, M. et al. Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma. Genome Med. 5, 15 (2013).
  CAS PubMed PubMed Central Google Scholar
• Burgers, W. A. et al. Viral oncoproteins target the DNA methyltransferases. Oncogene 26, 1650–1655 (2007).
  CAS PubMed Google Scholar
• Chalertpet, K., Pakdeechaidan, W., Patel, V., Mutirangura, A. & Yanatatsaneejit, P. Human papillomavirus type 16 E7 oncoprotein mediates CCNA1 promoter methylation. Cancer Sci. 106, 1333–1340 (2015).
  CAS PubMed PubMed Central Google Scholar
• Cicchini, L. et al. Suppression of antitumor immune responses by human papillomavirus through epigenetic downregulation of CXCL14. mBio 7, e00270-16 (2016).
  PubMed PubMed Central Google Scholar
• Cicchini, L. et al. High-risk human papillomavirus E7 alters host DNA methylome and represses HLA-E expression in human keratinocytes. Sci. Rep. 7, 3633 (2017).
  PubMed PubMed Central Google Scholar
• Munger, K. & Jones, D. L. Human papillomavirus carcinogenesis: an identity crisis in the retinoblastoma tumor suppressor pathway. J. Virol. 89, 4708–4711 (2015).
  CAS PubMed PubMed Central Google Scholar
• Magaldi, T. G. et al. Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation. Virology 422, 114–124 (2012).
  CAS PubMed Google Scholar
• Weinstein, I. B. Addiction to oncogenes–the Achilles heal of cancer. Science 297, 63–64 (2002).
  CAS PubMed Google Scholar
• McLaughlin-Drubin, M. E., Crum, C. P. & Münger, K. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc. Natl Acad. Sci. USA 108, 2130–2135 (2011).
  CAS PubMed PubMed Central Google Scholar
• McLaughlin-Drubin, M. E., Park, D. & Munger, K. Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines. Proc. Natl Acad. Sci. USA 110, 16175–16180 (2013).
  CAS PubMed PubMed Central Google Scholar
• Spring, L. M. et al. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet 395, 817–827 (2020).
  CAS PubMed Google Scholar
• Soto, D. R., Barton, C., Munger, K. & McLaughlin-Drubin, M. E. KDM6A addiction of cervical carcinoma cell lines is triggered by E7 and mediated by p21CIP1 suppression of replication stress. PLoS Pathog. 13, 1–25 (2017).
  Google Scholar
• Ganti, K. et al. The human papillomavirus E6 PDZ binding motif: from life cycle to malignancy. Viruses 7, 3530–3551 (2015).
  CAS PubMed PubMed Central Google Scholar
• Mittal, S. & Banks, L. Molecular mechanisms underlying human papillomavirus E6 and E7 oncoprotein-induced cell transformation. Mutat. Res. 772, 23–35 (2017).
  CAS Google Scholar
• Roman, A. & Munger, K. The papillomavirus E7 proteins. Virology 445, 138–168 (2013).
  CAS PubMed Google Scholar
• Moody, C. A. & Laimins, L. A. Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer 10, 550–560 (2010).
  CAS PubMed Google Scholar
• Seiwert, T. Y. et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin. Cancer Res. 21, 632–641 (2015).
  CAS PubMed Google Scholar
• The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517, 576–582 (2015).
  Google Scholar
• Gillison, M. L. et al. Human papillomavirus and the landscape of secondary genetic alterations in oral cancers. Genome Res. 29, 1–17 (2019).
  CAS PubMed PubMed Central Google Scholar
• Dogan, S. et al. Identification of prognostic molecular biomarkers in 157 HPV-positive and HPV-negative squamous cell carcinomas of the oropharynx. Int. J. Cancer 145, 3152–3162 (2019).
  CAS PubMed PubMed Central Google Scholar
• Lechner, M. et al. Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV− tumors. Genome Med. 5, 49 (2013).
  PubMed PubMed Central Google Scholar
• Hayes, D. N., Van Waes, C. & Seiwert, T. Y. Genetic landscape of human papillomavirus-associated head and neck cancer and comparison to tobacco-related tumors. J. Clin. Oncol. 33, 3227–3234 (2015).
  CAS PubMed PubMed Central Google Scholar
• Henderson, S., Chakravarthy, A., Su, X., Boshoff, C. & Fenton, T. R. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep. 7, 1833–1841 (2014).
  CAS PubMed Google Scholar
• Zhu, B. et al. Mutations in the HPV16 genome induced by APOBEC3 are associated with viral clearance. Nat. Commun. 11, 1–12 (2020).
  Google Scholar
• Faden, D. L. et al. APOBEC mutagenesis is concordant between tumor and viral genomes in HPV-positive head and neck squamous cell carcinoma. Viruses 13, 1666 (2021).
  CAS PubMed PubMed Central Google Scholar
• Smith, N. J. & Fenton, T. R. The APOBEC3 genes and their role in cancer: insights from human papillomavirus. J. Mol. Endocrinol. 62, R269–R287 (2019).
  CAS PubMed Google Scholar
• Fenton, T. R. Accumulation of host cell genetic errors following high-risk HPV infection. Curr. Opin. Virol. 51, 1–8 (2021).
  CAS PubMed Google Scholar
• Warren, C. J., Westrich, J. A., Van Doorslaer, K. & Pyeon, D. Roles of APOBEC3A and APOBEC3B in human papillomavirus infection and disease progression. Viruses 9, 1–20 (2017).
  Google Scholar
• Lui, V. W. Y. et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 3, 761–769 (2013).
  CAS PubMed PubMed Central Google Scholar
• Nichols, A. C. et al. High frequency of activating PIK3CA mutations in human papillomavirus- positive oropharyngeal cancer. JAMA Otolaryngol. 139, 617–622 (2013).
  Google Scholar
• Hanna, G. J. et al. Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer. JCI Insight 3, e122799 (2018).
  PubMed Central Google Scholar
• Beaty, B. T. et al. PIK3CA mutation in HPV-associated OPSCC patients receiving deintensified chemoradiation. J. Natl Cancer Inst. 112, 855–858 (2019).
  Google Scholar
• Hedberg, M. L. et al. Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer. J. Exp. Med. 216, 419–427 (2019).
  CAS PubMed PubMed Central Google Scholar
• Cai, Y., Yousef, A., Grandis, J. R. & Johnson, D. E. NSAID therapy for PIK3CA-altered colorectal, breast, and head and neck cancer. Adv. Biol. Regul. 75, 100653 (2020).
  PubMed Google Scholar
• Paleari, L. et al. PIK3CA mutation, aspirin use after diagnosis and survival of colorectal cancer. a systematic review and meta-analysis of epidemiological studies. Clin. Oncol. 28, 317–326 (2016).
  CAS Google Scholar
• Nyman, P. E., Buehler, D. & Lambert, P. F. Loss of function of canonical Notch signaling drives head and neck carcinogenesis. Clin. Cancer Res. 24, 6308–6318 (2018).
  PubMed PubMed Central Google Scholar
• Kranjec, C. et al. Modulation of basal cell fate during productive and transforming HPV-16 infection is mediated by progressive E6-driven depletion of Notch. J. Pathol. 242, 448–462 (2017).
  CAS PubMed PubMed Central Google Scholar
• Beglin, M., Melar-New, M. & Laimins, L. Human papillomaviruses and the interferon response. J. Interf. Cytokine Res. 29, 629–635 (2009).
  CAS Google Scholar
• Dhawan, A. et al. Role of gene signatures combined with pathology in classification of oropharynx head and neck cancer. Sci. Rep. 10, 10226 (2020).
  CAS PubMed PubMed Central Google Scholar
• She, Y. et al. Immune-related gene signature for predicting the prognosis of head and neck squamous cell carcinoma. Cancer Cell Int. 20, 22 (2020).
  PubMed PubMed Central Google Scholar
• Chan, T. A. et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann. Oncol. 30, 44–56 (2019).
  CAS PubMed Google Scholar
• McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463–1469 (2016).
  CAS PubMed PubMed Central Google Scholar
• Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331, 1565–1570 (2011).
  CAS PubMed Google Scholar
• Steinbach, A. & Riemer, A. B. Immune evasion mechanisms of human papillomavirus: an update. Int. J. Cancer 142, 224–229 (2018).
  CAS PubMed Google Scholar
• Ashrafi, G. H., Haghshenas, M. R., Marchetti, B., O’Brien, P. M. & Campo, M. S. E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int. J. Cancer 113, 276–283 (2005).
  CAS PubMed Google Scholar
• Ashrafi, G. H., Haghshenas, M., Marchetti, B. & Campo, M. S. E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int. J. Cancer 119, 2105–2112 (2006).
  CAS PubMed Google Scholar
• Campo, M. S. et al. HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology 407, 137–142 (2010).
  CAS PubMed Google Scholar
• Georgopoulos, N. T., Proffitt, J. L. & Blair, G. E. Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins. Oncogene 19, 4930–4935 (2000).
  CAS PubMed Google Scholar
• Li, H., Ou, X., Xiong, J. & Wang, T. HPV16E7 mediates HADC chromatin repression and downregulation of MHC class I genes in HPV16 tumorigenic cells through interaction with an MHC class I promoter. Biochem. Biophys. Res. Commun. 349, 1315–1321 (2006).
  CAS PubMed Google Scholar
• Bottley, G. et al. High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells. Oncogene 27, 1794–1799 (2008).
  CAS PubMed Google Scholar
• Heusinkveld, M. et al. Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer. Int. J. Cancer 131, 74–85 (2012).
  Google Scholar
• Welters, M. J. P. et al. Intratumoral HPV16-specific T cells constitute a type I-oriented tumor microenvironment to improve survival in HPV16-driven oropharyngeal cancer. Clin. Cancer Res. 24, 634–647 (2018).
  CAS PubMed Google Scholar
• Santegoets, S. J. et al. The anatomical location shapes the immune infiltrate in tumors of same etiology and affects survival. Clin. Cancer Res. 25, 240–252 (2019).
  CAS PubMed Google Scholar
• Santegoets, S. J. et al. CD163+ cytokine-producing cDC2 stimulate intratumoral type 1 T cell responses in HPV16-induced oropharyngeal cancer. J. Immunother. Cancer 8, e001053 (2020).
  PubMed PubMed Central Google Scholar
• Hoffmann, T. K. et al. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int. J. Cancer 118, 1984–1991 (2006).
  CAS PubMed Google Scholar
• Masterson, L. et al. CD8+ T cell response to human papillomavirus 16 E7 is able to predict survival outcome in oropharyngeal cancer. Eur. J. Cancer 67, 141–151 (2016).
  CAS PubMed Google Scholar
• Laban, S. & Hoffmann, T. K. Human papillomavirus immunity in oropharyngeal cancer: time to change the game? Clin. Cancer Res. 24, 505–507 (2018).
  CAS PubMed Google Scholar
• Balermpas, P. et al. CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: a multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Int. J. Cancer 138, 171–181 (2016).
  CAS PubMed Google Scholar
• Ward, M. J. et al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br. J. Cancer 110, 489–500 (2014).
  CAS PubMed Google Scholar
• Mandal, R. et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 1, e89829 (2016).
  PubMed PubMed Central Google Scholar
• Chakravarthy, A. et al. Human papillomavirus drives tumor development throughout the head and neck: improved prognosis is associated with an immune response largely restricted to the oropharynx. J. Clin. Oncol. 34, 4132–4141 (2016).
  CAS PubMed PubMed Central Google Scholar
• Li, H. et al. Association of human papillomavirus status at head and neck carcinoma subsites with overall survival. JAMA Otolaryngol. 144, 519–525 (2018).
  Google Scholar
• Hladíková, K. et al. Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8+ T cells. J. Immunother. Cancer 7, 261 (2019).
  PubMed PubMed Central Google Scholar
• Wood, O. et al. Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors. Oncotarget 7, 56781–56797 (2016).
  PubMed PubMed Central Google Scholar
• Ou, D. et al. Influence of tumor-associated macrophages and HLA class I expression according to HPV status in head and neck cancer patients receiving chemo/bioradiotherapy. Radiother. Oncol. 130, 89–96 (2019).
  PubMed Google Scholar
• Welters, M. J. P., Santegoets, S. J. & van der Burg, S. H. The tumor microenvironment and immunotherapy of oropharyngeal squamous cell carcinoma. Front. Oncol. 10, 545385 (2020).
  PubMed PubMed Central Google Scholar
• Hong, A. M. et al. Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer. Oral. Oncol. 92, 33–39 (2019).
  CAS PubMed Google Scholar
• Cao, S. et al. Dynamic host immune response in virus-associated cancers. Commun. Biol. 2, 109 (2019).
  PubMed PubMed Central Google Scholar
• McIlwain, W. R., Sood, A. J., Nguyen, S. A. & Day, T. A. Initial symptoms in patients with HPV-positive and HPV-negative oropharyngeal cancer. JAMA Otolaryngol. 140, 441–447 (2014).
  Google Scholar
• Khalid, M. B. et al. Initial presentation of human papillomavirus-related head and neck cancer: a retrospective review. Laryngoscope 129, 877–882 (2019).
  PubMed Google Scholar
• Tham, T., Ahn, S., Frank, D., Kraus, D. & Costantino, P. Anatomical subsite modifies survival in oropharyngeal squamous cell carcinoma: National Cancer Database study. Head. Neck 42, 434–445 (2020).
  PubMed Google Scholar
• Golusinski, P. et al. Evidence for the approach to the diagnostic evaluation of squamous cell carcinoma occult primary tumors of the head and neck. Oral. Oncol. 88, 145–152 (2019).
  PubMed Google Scholar
• Zhang, M. Q., El-Mofty, S. K. & Dávila, R. M. Detection of human papillomavirus-related squamous cell carcinoma cytologically and by in situ hybridization in fine-needle aspiration biopsies of cervical metastasis: a tool for identifying the site of an occult head and neck primary. Cancer 114, 118–123 (2008).
  PubMed Google Scholar
• Begum, S., Gillison, M. L., Nicol, T. L. & Westra, W. H. Detection of human papillomavirus-16 in fine-needle aspirates to determine tumor origin in patients with metastatic squamous cell carcinoma of the head and neck. Clin. Cancer Res. 13, 1186–1191 (2007).
  CAS PubMed Google Scholar
• Mehanna, H. et al. Oropharyngeal cancer: United Kingdom National Multidisciplinary Guidelines. J. Laryngol. Otol. 130, S90–S96 (2016).
  CAS PubMed PubMed Central Google Scholar
• Gage, K. L., Thomas, K., Jeong, D., Stallworth, D. G. & Arrington, J. A. Multimodal imaging of head and neck squamous cell carcinoma. Cancer Control. 24, 172–179 (2017).
  PubMed Google Scholar
• Schache, A. G. et al. Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin. Cancer Res. 17, 6262–6271 (2011).
  CAS PubMed PubMed Central Google Scholar
• Lewis, J. S. Morphologic diversity in human papillomavirus-related oropharyngeal squamous cell carcinoma: catch me if you can! Mod. Pathol. 30, S44–S53 (2017).
  PubMed Google Scholar
• Chernock, R. D., Lewis, J. S., Zhang, Q. & El-Mofty, S. K. Human papillomavirus-positive basaloid squamous cell carcinomas of the upper aerodigestive tract: a distinct clinicopathologic and molecular subtype of basaloid squamous cell carcinoma. Hum. Pathol. 41, 1016–1023 (2010).
  CAS PubMed Google Scholar
• Cho, K. J. et al. Basaloid squamous cell carcinoma of the head and neck: subclassification into basal, ductal, and mixed subtypes based on comparison of clinico-pathologic features and expression of p53, cyclin D1, epidermal growth factor receptor, p16, and human papilloma. J. Pathol. Transl. Med. 51, 374–380 (2017).
  PubMed PubMed Central Google Scholar
• Mehrad, M. et al. Papillary squamous cell carcinoma of the head and neck: clinicopathologic and molecular features with special reference to human papillomavirus. Am. J. Surg. Pathol. 37, 1349–1356 (2013).
  PubMed PubMed Central Google Scholar
• Carpenter, D. H., El-Mofty, S. K. & Lewis, J. S. Undifferentiated carcinoma of the oropharynx: a human papillomavirus-associated tumor with a favorable prognosis. Mod. Pathol. 24, 1306–1312 (2011).
  CAS PubMed Google Scholar
• Singhi, A. D., Stelow, E. B., Mills, S. E. & Westra, W. H. Lymphoepithelial-like carcinoma of the oropharynx: a morphologic variant of HPV-related head and neck carcinoma. Am. J. Surg. Pathol. 34, 800–805 (2010).
  PubMed Google Scholar
• Jo, V. Y., Mills, S. E., Stoler, M. H. & Stelow, E. B. Papillary squamous cell carcinoma of the head and neck: frequent association with human papillomavirus infection and invasive carcinoma. Am. J. Surg. Pathol. 33, 1720–1724 (2009).
  PubMed Google Scholar
• Bryne, M., Koppang, H. S., Lilleng, R. & Kjærheim, Å. Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value. J. Pathol. 166, 375–381 (1992).
  CAS PubMed Google Scholar
• Albergotti, W. G. et al. Defining the prevalence and prognostic value of perineural invasion and angiolymphatic invasion in human papillomavirus-positive oropharyngeal carcinoma. JAMA Otolaryngol. 143, 1236–1243 (2017).
  Google Scholar
• Dirven, R. et al. Tumor thickness versus depth of invasion – analysis of the 8th edition American Joint Committee on Cancer Staging for oral cancer. Oral. Oncol. 74, 30–33 (2017).
  PubMed Google Scholar
• Zhan, K. Y. et al. Appraisal of the AJCC 8th edition pathologic staging modifications for HPV−positive oropharyngeal cancer, a study of the National Cancer Data Base. Oral. Oncol. 73, 152–159 (2017).
  PubMed Google Scholar
• Elicin, O. et al. Comparison of contemporary staging systems for oropharynx cancer in a surgically treated multi-institutional cohort. Head. Neck 41, 1395–1402 (2019).
  PubMed Google Scholar
• Bhattasali, O., Thompson, L. D. R., Schumacher, A. J. & Iganej, S. Radiographic nodal prognostic factors in stage I HPV-related oropharyngeal squamous cell carcinoma. Head. Neck 41, 398–402 (2019).
  PubMed Google Scholar
• Sinha, P. et al. High metastatic node number, not extracapsular spread or N-classification is a node-related prognosticator in transorally-resected, neck-dissected p16-positive oropharynx cancer. Oral. Oncol. 51, 514–520 (2015).
  PubMed Google Scholar
• Bauer, E. et al. Extranodal extension is a strong prognosticator in HPV-positive oropharyngeal squamous cell carcinoma. Laryngoscope 130, 939–945 (2020).
  CAS PubMed Google Scholar
• Freitag, J. et al. Extracapsular extension of neck nodes and absence of human papillomavirus 16-DNA are predictors of impaired survival in p16-positive oropharyngeal squamous cell carcinoma. Cancer 126, 1856–1872 (2020).
  CAS PubMed Google Scholar
• Tian, S. et al. Prognostic value of radiographically defined extranodal extension in human papillomavirus-associated locally advanced oropharyngeal carcinoma. Head. Neck 41, 3056–3063 (2019).
  PubMed PubMed Central Google Scholar
• Meyer, M. F. et al. The relevance of the lymph node ratio as predictor of prognosis is higher in HPV-negative than in HPV-positive oropharyngeal squamous cell carcinoma. Clin. Otolaryngol. 43, 192–198 (2018).
  CAS PubMed Google Scholar
• Chai, R. L. et al. Accuracy of computed tomography in the prediction of extracapsular spread of lymph node metastases in squamous cell carcinoma of the head and neck. JAMA Otolaryngol. 139, 1187–1194 (2013).
  Google Scholar
• Aiken, A. H. et al. Accuracy of preoperative imaging in detecting nodal extracapsular spread in oral cavity squamous cell carcinoma. Am. J. Neuroradiol. 36, 1776–1781 (2015).
  CAS PubMed PubMed Central Google Scholar
• Carlton, J. A. et al. Computed tomography detection of extracapsular spread of squamous cell carcinoma of the head and neck in metastatic cervical lymph nodes. Neuroradiol. J. 30, 222–229 (2017).
  PubMed PubMed Central Google Scholar
• Douglas, C. et al. Accuracy of contrast-enhanced CT and predictive factors for extracapsular spread in unknown primary head and neck squamous cell cancer. Clin. Radiol. 75, 77.e23–77.e28 (2020).
  CAS Google Scholar
• O’Sullivan, B. et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 17, 440–451 (2016).
  PubMed Google Scholar
• Cramer, J. D., Hicks, K. E., Rademaker, A. W., Patel, U. A. & Samant, S. Validation of the eighth edition American Joint Committee on Cancer staging system for human papillomavirus-associated oropharyngeal cancer. Head. Neck 40, 457–466 (2018).
  PubMed Google Scholar
• Geltzeiler, M. et al. Staging HPV-related oropharyngeal cancer: validation of AJCC-8 in a surgical cohort. Oral. Oncol. 84, 82–87 (2018).
  PubMed PubMed Central Google Scholar
• Van Gysen, K. et al. Validation of the 8th edition UICC/AJCC TNM staging system for HPV associated oropharyngeal cancer patients managed with contemporary chemo-radiotherapy. BMC Cancer 19, 674 (2019).
  PubMed PubMed Central Google Scholar
• Würdemann, N. et al. Prognostic impact of AJCC/UICC 8th edition new staging rules in oropharyngeal squamous cell carcinoma. Front. Oncol. 7, 129 (2017).
  PubMed PubMed Central Google Scholar
• Nauta, I. H. et al. Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional HPV DNA testing. Ann. Oncol. 29, 1273–1279 (2018).
  CAS PubMed Google Scholar
• Fakhry, C. et al. Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: implications for risk-based therapeutic intensity trials. Cancer 125, 2027–2038 (2019).
  CAS PubMed Google Scholar
• Haeggblom, L., Ramqvist, T., Tommasino, M. & Dalianis, T. Time to change perspectives on HPV in oropharyngeal cancer. A systematic review of HPV prevalence per oropharyngeal sub-site the last 3 years. Papillomavirus Res. 4, 1–11 (2017).
  PubMed PubMed Central Google Scholar
• Wendt, M. et al. Long-term survival and recurrence in oropharyngeal squamous cell carcinoma in relation to subsites, HPV, and p16-status. Cancers (Basel) 13, 2553 (2021).
  CAS Google Scholar
• Ellis, M. et al. Post-treatment head and neck cancer care: national audit and analysis of current practice in the United Kingdom. Clin. Otolaryngol. 46, 284–294 (2021).
  PubMed Google Scholar
• Fakhry, C. et al. Association of oral human papillomavirus DNA persistence with cancer progression after primary treatment for oral cavity and oropharyngeal squamous cell carcinoma. JAMA Oncol. 5, 985–992 (2019).
  PubMed PubMed Central Google Scholar
• Chera, B. S. et al. Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. J. Clin. Oncol. 38, 1050–1058 (2020).
  CAS PubMed PubMed Central Google Scholar
• Holsinger, F. C. & Ferris, R. L. Transoral endoscopic head and neck surgery and its role within the multidisciplinary treatment paradigm of oropharynx cancer: robotics, lasers, and clinical trials. J. Clin. Oncol. 33, 3285–3292 (2015).
  CAS PubMed PubMed Central Google Scholar
• Sinha, P., Haughey, B. H., Kallogjeri, D. & Jackson, R. S. Long-term analysis of transorally resected p16 + oropharynx cancer: outcomes and prognostic factors. Laryngoscope 129, 1141–1149 (2019).
  CAS PubMed Google Scholar
• Mahmoud, O., Sung, K., Civantos, F. J., Thomas, G. R. & Samuels, M. A. Transoral robotic surgery for oropharyngeal squamous cell carcinoma in the era of human papillomavirus. Head Neck 40, 710–721 (2018).
  PubMed Google Scholar
• Jackson, R. S. et al. Transoral resection of human papillomavirus (HPV)-positive squamous cell carcinoma of the oropharynx: outcomes with and without adjuvant therapy. Ann. Surg. Oncol. 24, 3494–3501 (2017).
  PubMed PubMed Central Google Scholar
• Carey, R. M. et al. Increased rate of recurrence and high rate of salvage in patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma with adverse features treated with primary surgery without recommended adjuvant therapy. Head Neck 43, 1128–1141 (2021).
  PubMed Google Scholar
• Sethia, R. et al. Quality of life outcomes of transoral robotic surgery with or without adjuvant therapy for oropharyngeal cancer. Laryngoscope 128, 403–411 (2018).
  PubMed Google Scholar
• Ma, D. J. et al. Phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus-associated oropharynx squamous cell carcinoma. J. Clin. Oncol. 37, 1909–1918 (2019).
  CAS PubMed PubMed Central Google Scholar
• Hargreaves, S., Beasley, M., Hurt, C., Jones, T. M. & Evans, M. Deintensification of adjuvant treatment after transoral surgery in patients with human papillomavirus-positive oropharyngeal cancer: the conception of the PATHOS study and its development. Front Oncol. 9, 936 (2019).
  PubMed PubMed Central Google Scholar
• Ferris, R. L. et al. Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: a trial of the ECOG-ACRIN cancer research group (E3311). J. Clin. Oncol. 39, 6010 (2021).
  Google Scholar
• Ferris, R. L. et al. Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3311). J. Clin. Oncol. 38, 6500 (2020).
  Google Scholar
• Ferris, R. L. et al. Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN Cancer Research Group trial (E3311). J. Clin. Oncol. 40, 138–149 (2022).
  CAS PubMed Google Scholar
• Chera, B. S. et al. Phase 2 trial of de-intensified chemoradiation therapy for favorable-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 93, 976–985 (2015).
  PubMed Google Scholar
• Chera, B. S. et al. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma. Cancer 124, 2347–2354 (2018).
  CAS PubMed Google Scholar
• Pearlstein, K. A. et al. Quality of life for patients with favorable-risk HPV-associated oropharyngeal cancer after de-intensified chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 103, 646–653 (2019).
  PubMed Google Scholar
• Seiwert, T. Y. et al. Optima: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann. Oncol. 30, 297–302 (2019).
  CAS PubMed Google Scholar
• Marur, S. et al. E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx-ECOG-ACRIN cancer research group. J. Clin. Oncol. 35, 490–497 (2017).
  CAS PubMed Google Scholar
• Hegde, J. V. et al. Functional outcomes after de-escalated chemoradiation therapy for human papillomavirus-positive oropharyngeal cancer: secondary analysis of a phase 2 trial. Int. J. Radiat. Oncol. Biol. Phys. 100, 647–651 (2018).
  PubMed Google Scholar
• Chen, A. M. et al. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. Lancet Oncol. 18, 803–811 (2017).
  PubMed PubMed Central Google Scholar
• Yamamoto, Y. et al. Radiotherapy alone as a possible de-intensified treatment for human papillomavirus-related locally advanced oropharyngeal squamous cell carcinoma. Int. J. Clin. Oncol. 24, 640–648 (2019).
  PubMed Google Scholar
• Hall, S. F., Griffiths, R. J., O’Sullivan, B. & Liu, F. F. The addition of chemotherapy to radiotherapy did not reduce the rate of distant metastases in low-risk HPV-related oropharyngeal cancer in a real-world setting. Head Neck 41, 2271–2276 (2019).
  PubMed PubMed Central Google Scholar
• Yom, S. S. et al. Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002). J. Clin. Oncol. 39, 956–965 (2021).
  CAS PubMed PubMed Central Google Scholar
• Sher, D. J. et al. Radiation therapy for oropharyngeal squamous cell carcinoma: executive summary of an ASTRO evidence-based clinical practice guideline. Pract. Radiat. Oncol. 7, 246–253 (2017).
  PubMed Google Scholar
• Howard, J. et al. Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small-volume primary oropharyngeal carcinoma. Cochrane Database Syst. Rev. 12, CD010963 (2016).
  PubMed Google Scholar
• Nichols, A. C. et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncol. 20, 1349–1359 (2019).
  CAS PubMed Google Scholar
• Ferris, R. L. et al. A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group trial E3311. Oral. Oncol. 110, 104797 (2020).
  PubMed PubMed Central Google Scholar
• de Almeida, J. R. et al. Oncologic outcomes after transoral robotic surgery: a multi-institutional study. JAMA Otolaryngol. 141, 1043–1051 (2015).
  Google Scholar
• Mehanna, H. et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 393, 51–60 (2019).
  CAS PubMed PubMed Central Google Scholar
• Gillison, M. L. et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 393, 40–50 (2019).
  CAS PubMed Google Scholar
• Oosthuizen, J. C. & Doody, J. De-intensified treatment in human papillomavirus-positive oropharyngeal cancer. Lancet 393, 5–7 (2019).
  PubMed Google Scholar
• Guo, T. et al. Characterization of functionally active gene fusions in human papillomavirus related oropharyngeal squamous cell carcinoma. Int. J. Cancer 139, 373–382 (2016).
  CAS PubMed PubMed Central Google Scholar
• Dunn, L. A. et al. Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer. Head. Neck 40, 233–241 (2018).
  PubMed Google Scholar
• Frazer, I. H. & Chandra, J. Immunotherapy for HPV associated cancer. Papillomavirus Res. 8, 100176 (2019).
  PubMed PubMed Central Google Scholar
• Barra, F. et al. Advances in therapeutic vaccines for treating human papillomavirus-related cervical intraepithelial neoplasia. J. Obstet. Gynaecol. Res. 46, 989–1006 (2020).
  PubMed Google Scholar
• Smalley Rumfield, C., Pellom, S. T., Morillon, Y. M., Schlom, J. & Jochems, C. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. J. Immunother. Cancer https://doi.org/10.1136/jitc-2020-000612 (2020).
  Article PubMed PubMed Central Google Scholar
• Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856–1867 (2016).
  PubMed PubMed Central Google Scholar
• Cohen, E. E. W. et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 393, 156–167 (2019).
  CAS PubMed Google Scholar
• Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394, 1915–1928 (2019).
  CAS PubMed Google Scholar
• Xu, Y. et al. Programmed death-1/programmed death-ligand 1-axis blockade in recurrent or metastatic head and neck squamous cell carcinoma stratified by human papillomavirus status: a systematic review and meta-analysis. Front. Immunol. 12, 645170 (2021).
  CAS PubMed PubMed Central Google Scholar
• Wang, J. et al. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma. Sci. Rep. 9, 13404 (2019).
  PubMed PubMed Central Google Scholar
• Galvis, M. M. et al. Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 150, 102966 (2020).
  PubMed Google Scholar
• Patel, J. J., Levy, D. A., Nguyen, S. A., Knochelmann, H. M. & Day, T. A. Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma — systematic review and meta-analysis. Head Neck 42, 774–786 (2019).
  PubMed PubMed Central Google Scholar
• Wong, D. J. et al. Abstract CT123: IMvoke010: randomized phase III study of atezolizumab as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck. Cancer Res. 79, (Suppl.) 13 (2019).
  Google Scholar
• Leidner, R. et al. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma. J. Immunother. Cancer 9, e002485 (2021).
  PubMed PubMed Central Google Scholar
• Ferris, R. L. et al. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. J. Immunother. Cancer 9, e002568 (2021).
  PubMed PubMed Central Google Scholar
• Ferrarotto, R. et al. Impact of neoadjuvant durvalumab with or without tremelimumab on CD8+ tumor lymphocyte density, safety, and efficacy in patients with oropharynx cancer: CIAO trial results. Clin. Cancer Res. 26, 3211–3219 (2020).
  CAS PubMed PubMed Central Google Scholar
• von Witzleben, A., Wang, C., Laban, S., Savelyeva, N. & Ottensmeier, C. H. HNSCC: tumour antigens and their targeting by immunotherapy. Cells 9, 2103 (2020).
  Google Scholar
• Massarelli, E. et al. Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial. JAMA Oncol. 5, 67–73 (2019).
  PubMed Google Scholar
• Aggarwal, C. et al. Immunotherapy targeting HPV16/18 generates potent immune responses in HPV-associated head and neck cancer. Clin. Cancer Res. 25, 110–124 (2019).
  CAS PubMed Google Scholar
• Fakhry, C. et al. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J. Clin. Oncol. 32, 3365–3373 (2014).
  PubMed PubMed Central Google Scholar
• Harbison, R. A. et al. The mutational landscape of recurrent versus nonrecurrent human papillomavirus-related oropharyngeal cancer. JCI insight 3, e99327 (2018).
  PubMed Central Google Scholar
• Gleber-netto, F. O. et al. Variations in HPV function are associated with survival in squamous cell carcinoma. JCI Insight 4, e124762 (2019).
  PubMed Central Google Scholar
• King, A. and Broggio, J. Cancer Registration Statistics, England https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/final2016 (2016).
• Surveillance Research Program SEER Incidence Data, 1975–2018. https://seer.cancer.gov/data/ (National Cancer Institute, 2020).
• Lechner, M. & Fenton, T. R. The genomics, epigenomics, and transcriptomics of HPV-associated oropharyngeal cancer — understanding the basis of a rapidly evolving disease. Adv. Genet. 93, 1–56 (2016).
  CAS PubMed Google Scholar
• Machczyński, P., Majchrzak, E., Niewinski, P., Marchlewska, J. & Golusiński, W. A review of the 8th edition of the AJCC staging system for oropharyngeal cancer according to HPV status. Eur. Arch. Otorhinolaryngol. 277, 2407–2412 (2020).
  PubMed PubMed Central Google Scholar
• Adelstein, D. J. et al. Role of treatment deintensification in the management of p16+ oropharyngeal cancer: ASCO provisional clinical opinion. J. Clin. Oncol. 37, 1578–1589 (2019).
  PubMed Google Scholar
• Posner, M. R. et al. Survival (OS) and progression-free survival (PFS) results after induction chemotherapy (IC) followed by de-escalated chemoradiotherapy (RDCRT) for locally advanced (LA) HPV positive oropharynx cancer (HPVOPC). J. Clin. Oncol. 39, 6058 (2021).
  Google Scholar
• Palma, D. A. et al. A randomized trial of radiotherapy vs. trans-oral surgery for treatment de-escalation in HPV-associated oropharyngeal squamous cell carcinoma (ORATOR2). Int. J. Rad. Oncol. Biophys. 111, 1324–1325 (2021).
  Google Scholar
• Miles, B. A. et al. De-escalated adjuvant therapy after transoral robotic surgery for human papillomavirus-related oropharyngeal carcinoma: the Sinai robotic surgery (SIRS) trial. Oncologist 26, 504–513 (2021).
  PubMed PubMed Central Google Scholar
• Swisher–McClure, S. et al. A phase 2 trial of Alternative Volumes of Oropharyngeal Irradiation for De-intensification (AVOID): omission of the resected primary tumor bed after transoral robotic surgery for human papilloma virus-related squamous cell carcinoma of the oropharynx. Int. J. Radiat. Oncol. Biol. Phys. 106, 725–732 (2020).
  PubMed Google Scholar